Analysts Expect iTeos Therapeutics, Inc. (NASDAQ:ITOS) Will Announce Earnings of $1.20 Per Share

Wall Street analysts expect iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) to report earnings per share (EPS) of $1.20 for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for iTeos Therapeutics’ earnings. The lowest EPS estimate is $0.08 and the highest is $3.13. iTeos Therapeutics reported earnings of ($0.75) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 260%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that iTeos Therapeutics will report full-year earnings of $4.38 per share for the current financial year, with EPS estimates ranging from $1.72 to $12.33. For the next fiscal year, analysts expect that the business will post earnings of ($2.85) per share, with EPS estimates ranging from ($6.63) to $1.54. Zacks’ EPS averages are an average based on a survey of analysts that cover iTeos Therapeutics.

iTeos Therapeutics (NASDAQ:ITOSGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $1.02. The firm had revenue of $152.52 million for the quarter, compared to analysts’ expectations of $63.30 million.

Separately, Piper Sandler dropped their price target on iTeos Therapeutics from $42.00 to $34.00 in a research report on Wednesday, May 11th.

Shares of NASDAQ ITOS traded up $0.25 during trading on Friday, reaching $17.09. 387,888 shares of the stock traded hands, compared to its average volume of 517,149. iTeos Therapeutics has a 52-week low of $16.21 and a 52-week high of $52.43. The company has a 50-day moving average of $27.46 and a 200-day moving average of $33.92. The stock has a market capitalization of $607.40 million, a P/E ratio of 2.19 and a beta of 1.94.

In related news, major shareholder Boxer Capital, Llc sold 575,201 shares of the business’s stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $35.25, for a total transaction of $20,275,835.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Yvonne Mcgrath sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $36.76, for a total value of $367,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,431,638 shares of company stock worth $40,058,468. 3.95% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in iTeos Therapeutics by 106.5% in the 1st quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock worth $107,203,000 after acquiring an additional 1,718,085 shares during the last quarter. RTW Investments LP increased its stake in iTeos Therapeutics by 37.1% in the 3rd quarter. RTW Investments LP now owns 2,353,015 shares of the company’s stock worth $63,531,000 after acquiring an additional 636,430 shares during the last quarter. State Street Corp increased its stake in iTeos Therapeutics by 124.3% in the 1st quarter. State Street Corp now owns 1,711,891 shares of the company’s stock worth $55,089,000 after acquiring an additional 948,540 shares during the last quarter. Vanguard Group Inc. increased its stake in iTeos Therapeutics by 39.1% in the 1st quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock worth $47,499,000 after acquiring an additional 415,232 shares during the last quarter. Finally, EcoR1 Capital LLC increased its position in shares of iTeos Therapeutics by 25.8% during the 3rd quarter. EcoR1 Capital LLC now owns 1,303,157 shares of the company’s stock valued at $35,185,000 after purchasing an additional 267,293 shares during the last quarter. Institutional investors and hedge funds own 94.71% of the company’s stock.

About iTeos Therapeutics (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Featured Stories

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.